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Decreases Incidence of Opioid-related 
Side Effects
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Background/Purpose: The addition of ultra-low-dose naloxone to patient-controlled analgesia (PCA) with
morphine reduces opioid-related side effects. Nalbuphine, a mixed opioid agonist–antagonist, may be
able to attenuate opioid-related side effects. The goal of the present study was to investigate the effect of
combined low-dose nalbuphine and morphine in PCA for postoperative pain control after gynecological
surgery.
Methods: This randomized, double-blind, controlled study enrolled 174 female patients who were under-
going total abdominal hysterectomy, myomectomy, or ovarian tumor excision. In the control group, the
PCA formula was 1 mg/mL pure morphine. In the study group, the PCA formula was 1 mg/mL morphine
and 10 μg/mL nalbuphine (1:100). Numerical rating score, PCA requirement, nausea, vomiting, use of
antiemetics, pruritus, use of antipruritics, and opioid-related adverse events were investigated at 1, 2, 4,
and 24 hours postoperatively.
Results: One hundred and sixty-nine patients completed the study: 86 in the control group and 83 in the
study group. The incidence of nausea was lower in the study group (41%) than in the control group (65%).
The incidence of vomiting, use of antiemetics, pruritus, and use of antipruritics did not differ between the
two groups. The numerical rating pain score and PCA requirements were not significantly different between
the two groups.
Conclusion: Combination of low-dose nalbuphine and morphine in PCA decreases the incidence of 
opioid-related nausea, without affecting the analgesia and PCA requirement. This novel combination can
improve the quality of PCA used for postoperative pain control after gynecological surgery. [J Formos Med
Assoc 2009;108(7):548–553]
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ORIGINAL ARTICLE
Nalbuphine is known as a mixed opioid agonist–
antagonist.1–3 Nalbuphine derives its analgesic
and sedative effects through kappa-opioid recep-
tors, and it may attenuate mu-opioid-receptor-
related side effects.4 Morphine is the popular
opioid used in patient-controlled analgesia (PCA).
However, morphine causes many side effects in-
cluding pruritus, nausea, vomiting, constipation,
urinary retention, respiratory depression, and 
sedation. Since morphine binds most readily to
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the mu-opioid receptor, and less well to the
kappa-receptor, this implies that the undesirable
side effects of morphine are likely related to the
mu-opioid receptor.4
The addition of ultra-low-dose naloxone to
postoperative morphine PCA can reduce opioid-
related side effects.5,6 Moreover, several studies
have tried to compare the effect of naloxone 
and nalbuphine on opioid-related side effects.7–9
However, no previous study has evaluated the 
effect of combining low-dose nalbuphine and
morphine in intravenous PCA. The goal of this
study was to investigate the effect of combined
low-lose nalbuphine and morphine in intrave-
nous PCA for postoperative pain control after 
gynecological surgery.
Materials and Methods
Patients
This randomized, double-blind, controlled study
enrolled 174 female patients aged 18–65 years
old with an American Society of Anesthesiolo-
gists (ASA) physical status of I, II, or III. They had
undergone one of the following gynecological
operations: total abdominal hysterectomy, myo-
mectomy, or ovarian tumor excision. The protocol
was approved by the National Taiwan University
Hospital Research Ethics Committee, and in-
formed consent was obtained. Patients who had
a history of drug abuse, chronic pain, or psychi-
atric disorders were excluded. The patients were
also excluded if they took sedatives, antiemetics,
or antipruritics within 24 hours before surgery.
Randomization and grouping
The PCA solutions were prepared by a nurse anes-
thetist. After reviewing the literature, the potency
difference between naloxone and nalbuphine was
judged to be about 25–50:1.7–10 After considering
the characteristic of PCA use and longer half-life
of nalbuphine, we decided to use a concentration
of 10 μg/mL in the study group. Compared with
the ultra-low-dose naloxone study,5 the potency
difference between naloxone and nalbuphine was
assumed as 16.7:1 in the present study. Patients
were randomly allocated into two groups using 
a computer-generated randomized number table.
In the control group, 100 mg preservative-free
morphine was added to normal saline to make 
a total volume of 100 mL. In the study group,
100 mg preservative-free morphine and 1 mg nal-
buphine were added to normal saline to make a
total volume of 100 mL. Before surgery, patients
were instructed in the 0–10 numerical rating score
(NRS) for pain and the use of PCA. A score of 0
represented no pain and 10 represented the worst
pain imaginable. The goal of PCA analgesia was
to maintain NRS at rest ≤ 4 between 4 and 24
hours postoperatively.
Anesthesia, postoperative analgesia and PCA
No patients received any drug for premedication.
Anesthesia was induced with thiopental (3–5 mg/
kg) and fentanyl (1.5–3 mg/kg), and maintained
with sevoflurane 1.2–1.5% in oxygen. Rocuro-
nium (0.8 mg/kg) was given to facilitate endo-
tracheal intubation and maintained at 0.2 mg/kg
every 30 minutes. At the end of surgery, atropine
(0.015 mg/kg) and neostigmine (0.05 mg/kg) were
administered for reversal of neuromuscular block.
After the trachea was extubated, patients were
transported to the postanesthesia care unit. During
the 1-hour stay there, vital signs were monitored
every 5 minutes and oxygen saturation was moni-
tored continuously by pulse oximetry. The patients
were attached to a PCA machine (Lifecare 5500
PCA; Abbott Laboratories, Abbott Park, IL, USA).
Postoperative analgesia was commenced with an
intravenous loading dose of 3 mL PCA solution,
administered by a nurse. Incremental doses of
1 mL PCA solution were given as needed. After
the patients were responsive, they were allowed
to use the PCA machine by themselves. The set-
ting for PCA was 1 mL bolus with a 5-minute
lockout. There was no background continuous
infusion throughout the postoperative period.
Postoperative evaluation
After transferring back to the general ward, all
patients were observed for 24 hours after surgery.
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The cumulative PCA requirements were recorded
in PCA machines, and the data were transferred
to a computer for interpretation. Pain intensity
was evaluated with a 0–10 NRS at rest. The inci-
dence of opioid-related side effects (nausea, vom-
iting, and pruritus) was evaluated. A vomiting
episode was defined as vomiting that occurred 
in a rapid sequence (< 1 minute between events),
and retching (same as vomiting but without ex-
pulsion of gastric contents). If vomiting events
were separated by longer than 1 minute, they were
considered as separate episodes. The total number
of vomiting episodes was recorded. Vomiting that
occurred more than four times within 24 hours
was considered as severe vomiting.11 Rescue anti-
emesis (intravenous prochlorperazine mesylate
10 mg) was given at the patient’s request. All data
were collected at 1, 2, 4 and 24 hours postopera-
tively by direct questioning from investigators.
Definition of treatment failure and 
adverse events
Treatment failures included insufficient analgesia,
intolerable nausea and vomiting, and pruritus.
Insufficient analgesia was defined as NRS > 4 at
rest during 4–24 hours postoperatively.5 Adjunc-
tive analgesia with 50 mg meperidine or 30 mg
ketorolac was administered intravenously for in-
sufficient analgesia. Intolerable nausea and vomit-
ing were defined as persistent nausea or vomiting
episodes that required more than three adminis-
trations of antiemetics (prochlorperazine mesy-
late). In this situation, the patient could decide
to use PCA continuously or receive nonsteroidal
anti-inflammatory drugs (NSAIDs; ketorolac) for
postoperative pain management. Intolerable pru-
ritus was defined as persistent pruritus that 
required more than three administrations of an-
tipruritics (diphenhydramine). In this situation,
the patient could decide to use PCA continuously
or receive NSAIDs (ketorolac) for postoperative
pain management.
PCA-related hypotension, allergic reaction,
bronchospasm, unconsciousness, and respiratory
depression were considered as adverse events.
Hypotension was defined as systolic blood pressure
< 90 mmHg at any investigated time. Respiratory
depression was defined as respiratory rate < 8 per
minute or hypoxemia (SpO2 < 90%). If adverse
events occurred, the use of PCA was stopped im-
mediately and the patient was observed closely.
Naloxone and oxygen supplementation were 
administered for respiratory depression.
Statistical analysis
In our previous study, the incidence of nausea in
morphine intravenous PCA was 67.6%.12 A sam-
ple size of 85 in each group was able to detect an
absolute 20% reduction of incidence of nausea
with an α level of 0.05 (one-sided) and a β level
of 0.2. Student’s t tests were conducted to examine
differences with respect to parametric variables,
such as patient characteristics, duration of surgery,
fentanyl use during operation, and PCA require-
ment. The Mann–Whitney U test was used to 
determine differences with respect to nonparamet-
ric variables, such as numerical rating score of pain
at rest. The incidence of nausea, vomiting, pruri-
tus, use of antiemetics, and use of antipruritics
were analyzed by the χ2 test. A value of p < 0.05
was considered to be statistically significant.
Results
One hundred and sixty-nine patients completed
this study: 86 in the control group, and 83 in the
study group. Five patients discontinued the in-
vestigation for the following reasons: three used
< 5 mL PCA solution (1 in the control group and
2 in the study group); one patient in the control
group used 84 mL PCA solution; and one patient
in the control group suffered from renal colic
caused by a renal stone (Figure). There was no
significant difference in demographic character-
istics, ASA classification, duration of surgery, or
intraoperative consumption of fentanyl between
the two groups (Table 1).
Pain intensity and PCA requirements
The NRS did not differ significantly between the
two groups throughout the observation period.
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The cumulative dose for PCA did not differ signif-
icantly between the two groups (Table 2). Three
patients experienced insufficient analgesia and
received adjunctive analgesics: one in the control
group and two in the study group.
Opioid-related side effects
The incidence of nausea was lower in the study
group (41%) than the control group (65%; Table
3). The incidence of vomiting seemed lower in
the study group than the control group, but the
difference was not significant. The incidence of
severe vomiting and the requirement for anti-
emetics did not differ significantly between the
two groups. The incidence of pruritus and use 
of antipruritics did not differ significantly be-
tween the two groups. No adverse events occurred
in this study. The combination of low-dose nal-
buphine and morphine in PCA decreased the 
incidence of opioid-related nausea by 37%. The
absolute reduction in the incidence of nausea was
24%, and the number needed to treat was 4.2. 
As a result of the sample size, the 11% absolute
reduction in the incidence of vomiting between
the two groups was not statistically significant.
We suggest further studies to investigate whether
vomiting is significantly reduced with nalbuphine
and morphine PCA.
Discussion
This study found that a combination of low-dose
nalbuphine and morphine in PCA did not affect
the analgesic effect or the PCA requirement. We
suggest that this combination can improve the
quality of PCA use.
The reduction in the incidence of opioid-
related nausea might result from blocking the 
excitatory effects of opioids.13 Nalbuphine is a
mixed opioid agonist–antagonist. Low-dose nal-
buphine may act like ultra-low-dose naloxone—
this can decrease the opioid-related side effects,
with unchanged analgesic and opioid require-
ments.5 Two studies have reported that ultra-
low doses of opioid antagonists enhance opioid
analgesia.14,15 However, in our study and another
using ultra-low-dose naloxone, the analgesia and
opioid requirement was unchanged. We suggest
that the combination ratio between opioid an-
tagonist and agonist is important for enhancing
opioid analgesia. In a previous using ultra-low-
dose naloxone,5 the incidence of pruritus was
lower after addition of naloxone to morphine
PCA. Moreover, several studies have reported
that nalbuphine infusion can reduce epidural
Low-dose nalbuphine in morphine PCA
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Patient selection
Inclusion criteria
Exclusion criteria
Patients enrolled
Standard anesthesia
Randomized PCA setting
Group 1 (n = 89)
Morphine 100 mg/mL
Group 2 (n = 85)
Morphine 100 mg/mL
Nalbuphine 1 mg/mL
Not analyzed (n = 3)
1 for PCA requirement 84 mg
1 for PCA requirement 5 mg
1 for renal colic (stone)
At postoperative 1 hr, 2 hr, 4 hr, 24 hr
Analgesic effects
 Pain score at rest and upon movement
 PCA requirements
Opioid-related side effects
 Nausea/vomiting
 Pruritus
 Dizziness
 Requirement of rescue agents
Treatment failure
 Insufficient analgesia
 Intolerable side effects
Adverse effects
 Hypotension
 Allergic reaction
 Bronchospasm
 Unconsciousness
 Respiratory depression
Evaluation
Not analyzed (n = 2)
2 for PCA requirement 4 mg
Analyzed (n = 86) Analyzed (n = 83)
Figure. Consort-type diagram of the study.
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morphine-related pruritus.7–10,16,17 In the present
study, the incidence of pruritus did not differ sig-
nificantly between the two groups. Compared
with the previous studies in which the total con-
sumption of nalbuphine for 24 hours was 1200–
60,000 μg, the mean consumption of nalbuphine
for 24 hours in our study was 247–257 μg. We
suggest that a higher dose of nalbuphine was
needed to reduce the incidence of opioid-related
pruritus. We suggest that the potency for each
opioid-related side effect might be different 
between naloxone and nalbuphine.
The results of this study were based on a pop-
ulation of women after gynecological surgery, and
the effect in a group of men might not be the
same. Several studies have revealed that nalbu-
phine has different effects in women and men.
Gear et al found an unexpected anti-analgesic 
effect in men receiving nalbuphine alone after
bone-impacted third molar extraction, compared
with women with a dose-dependent analgesic re-
sponse.18 They also reported that kappa-opioids
produce significantly greater analgesia in women
than in men.19 Therefore, we suggest that further
studies are needed to investigate whether the 
influence of nalbuphine on opioid-related side
effects differs between women and men.
In conclusion, the combination of low-dose
nalbuphine and morphine in PCA decreases the
incidence of opioid-related nausea. It does not
affect analgesia and PCA requirements. This novel
combination can improve the quality of PCA for
postoperative pain control after gynecological
surgery.
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